Back to Search
Start Over
Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris
- Source :
- Expert Opinion on Therapeutic Targets; March 2013, Vol. 17 Issue: 3 p293-306, 14p
- Publication Year :
- 2013
-
Abstract
- Introduction:Desmoglein 3 (Dsg3) is one of desmosomal cadherins and functions in epidermal keratinocyte adhesion. IgG anti-Dsg3 autoantibodies are detected in pemphigus vulgaris, an autoimmune bullous disease showing blisters and erosions on the skin and oral mucosa. Other types of pemphigus also show anti-Dsg3 antibodies. Genetic disease of Dsg3 has not been reported.Areas covered:Many in vitroand in vivostudies have indicated pathogenic role of anti-Dsg3 antibodies. Blisters in pemphigus vulgaris are thought to be developed by loss of keratinocyte adhesions by binding of anti-Dsg3 antibodies to Dsg3 through steric hindrance, internalization of Dsg3, changes in molecular integrity or signal transduction. There are pathogenic and nonpathogenic anti-Dsg3 antibodies reactive with different epitopes. Recent studies of pemphigus vulgaris include existence of non-Dsg3 autoantibodies, B cells and T cells reactive with Dsg3, involvement of TNF-α and IL-1 and activation of intracellular signaling.Expert opinion:Although systemic corticosteroids and immunosuppressive agents are mainstays for treatment of pemphigus, intravenous immunoglobulin, plasmapheresis, immunoadsorption, rituximab and TNF-α inhibitors are emerging. Anti-Dsg3 antibody-targeting therapies are reported in mouse model, but they are not yet available clinically. Clarification of pathogenic role of anti-Dsg3 antibodies in pemphigus should provide us with safer and more effective therapies.
Details
- Language :
- English
- ISSN :
- 14728222 and 17447631
- Volume :
- 17
- Issue :
- 3
- Database :
- Supplemental Index
- Journal :
- Expert Opinion on Therapeutic Targets
- Publication Type :
- Periodical
- Accession number :
- ejs29507428
- Full Text :
- https://doi.org/10.1517/14728222.2013.744823